196 related articles for article (PubMed ID: 24344137)
21. FRET and optical trapping reveal mechanisms of actin activation of the power stroke and phosphate release in myosin V.
Gunther LK; Rohde JA; Tang W; Cirilo JA; Marang CP; Scott BD; Thomas DD; Debold EP; Yengo CM
J Biol Chem; 2020 Dec; 295(51):17383-17397. PubMed ID: 33453985
[TBL] [Abstract][Full Text] [Related]
22. Myosin dilated cardiomyopathy mutation S532P disrupts actomyosin interactions, leading to altered muscle kinetics, reduced locomotion, and cardiac dilation in
Trujillo AS; Hsu KH; Puthawala J; Viswanathan MC; Loya A; Irving TC; Cammarato A; Swank DM; Bernstein SI
Mol Biol Cell; 2021 Aug; 32(18):1690-1706. PubMed ID: 34081531
[TBL] [Abstract][Full Text] [Related]
23. Electrostatic interaction of loop 1 and backbone of human cardiac myosin regulates the rate of ATP induced actomyosin dissociation.
Gargey A; Nesmelov YE
J Muscle Res Cell Motil; 2022 Mar; 43(1):1-8. PubMed ID: 34825297
[TBL] [Abstract][Full Text] [Related]
24. Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin.
Adhikari AS; Kooiker KB; Sarkar SS; Liu C; Bernstein D; Spudich JA; Ruppel KM
Cell Rep; 2016 Dec; 17(11):2857-2864. PubMed ID: 27974200
[TBL] [Abstract][Full Text] [Related]
25. Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function.
Schmitt JP; Debold EP; Ahmad F; Armstrong A; Frederico A; Conner DA; Mende U; Lohse MJ; Warshaw D; Seidman CE; Seidman JG
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14525-30. PubMed ID: 16983074
[TBL] [Abstract][Full Text] [Related]
26. A weak coupling mechanism for the early steps of the recovery stroke of myosin VI: A free energy simulation and string method analysis.
Blanc FEC; Houdusse A; Cecchini M
PLoS Comput Biol; 2024 Apr; 20(4):e1012005. PubMed ID: 38662764
[TBL] [Abstract][Full Text] [Related]
27. A Laing distal myopathy-associated proline substitution in the β-myosin rod perturbs myosin cross-bridging activity.
Buvoli M; Wilson GC; Buvoli A; Gugel JF; Hau A; Bönnemann CG; Paradas C; Ryba DM; Woulfe KC; Walker LA; Buvoli T; Ochala J; Leinwand LA
J Clin Invest; 2024 May; 134(9):. PubMed ID: 38690726
[TBL] [Abstract][Full Text] [Related]
28. Pooled Genetic Screenings to Identify Likely Pathogenic Variants in Hypertrophic Cardiomyopathy.
Georges A; Chahal CAA
Circ Genom Precis Med; 2024 Apr; 17(2):e004599. PubMed ID: 38497213
[No Abstract] [Full Text] [Related]
29. Cardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: Where Are We on the Hype Cycle?
Ommen SR
J Am Coll Cardiol; 2022 Jul; 80(2):109-110. PubMed ID: 35798444
[No Abstract] [Full Text] [Related]
30. Switch-1 instability at the active site decouples ATP hydrolysis from force generation in myosin II.
Walker BC; Walczak CE; Cochran JC
Cytoskeleton (Hoboken); 2021 Jan; 78(1):3-13. PubMed ID: 33381891
[TBL] [Abstract][Full Text] [Related]
31. Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential.
Rao SJ; Forst B; Kanwal AK; Kanwal A; Aronow WS; Naidu SS
Expert Opin Investig Drugs; 2023 Jan; 32(1):1-4. PubMed ID: 36625220
[No Abstract] [Full Text] [Related]
32. α-Myosin heavy chain (MYH6) in hypertrophic cardiomyopathy: Prominent expression in areas with vacuolar degeneration of myocardial cells.
Ntelios D; Meditskou S; Efthimiadis G; Pitsis A; Zegkos T; Parcharidou D; Theotokis P; Alexouda S; Karvounis H; Tzimagiorgis G
Pathol Int; 2022 May; 72(5):308-310. PubMed ID: 35166430
[No Abstract] [Full Text] [Related]
33. Myosin individualized: single nucleotide polymorphisms in energy transduction.
Burghardt TP; Neff KL; Wieben ED; Ajtai K
BMC Genomics; 2010 Mar; 11():172. PubMed ID: 20226094
[TBL] [Abstract][Full Text] [Related]
34. Identification of functional differences between recombinant human α and β cardiac myosin motors.
Deacon JC; Bloemink MJ; Rezavandi H; Geeves MA; Leinwand LA
Cell Mol Life Sci; 2012 Jul; 69(13):2261-77. PubMed ID: 22349210
[TBL] [Abstract][Full Text] [Related]
35. Ultrasound and genetic detection of fetal hypertrophic cardiomyopathy in second trimester of pregnancy.
Soares C; Lourenço C; Nogueira RN; Carrico A
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33408112
[No Abstract] [Full Text] [Related]
36. Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function.
Morck MM; Bhowmik D; Pathak D; Dawood A; Spudich J; Ruppel KM
Elife; 2022 Jun; 11():. PubMed ID: 35767336
[TBL] [Abstract][Full Text] [Related]
37. Structures and mechanisms of actin ATP hydrolysis.
Kanematsu Y; Narita A; Oda T; Koike R; Ota M; Takano Y; Moritsugu K; Fujiwara I; Tanaka K; Komatsu H; Nagae T; Watanabe N; Iwasa M; Maéda Y; Takeda S
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2122641119. PubMed ID: 36252034
[TBL] [Abstract][Full Text] [Related]
38. Switch-2 determines Mg
Diensthuber RP; Hartmann FK; Kathmann D; Franz P; Tsiavaliaris G
Front Physiol; 2024; 15():1393952. PubMed ID: 38887318
[TBL] [Abstract][Full Text] [Related]
39. Hypertrophic cardiomyopathy mutations in the calponin-homology domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation.
Haywood NJ; Wolny M; Rogers B; Trinh CH; Shuping Y; Edwards TA; Peckham M
Biochem J; 2016 Aug; 473(16):2485-93. PubMed ID: 27287556
[TBL] [Abstract][Full Text] [Related]
40. Familial hypertrophic cardiomyopathic myosin mutations that affect the actin-myosin interaction.
Roopnarine O
Results Probl Cell Differ; 2002; 36():75-86. PubMed ID: 11892286
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
